Anti-pyroptotic Function of TGF-β is Suppressed by a Synthetic DsRNA Analogue in Triple Negative Breast Cancer Cells

Overview

Journal Mol Oncol

Specialties Molecular Biology
Oncology

Date 2020 Dec 20

PMID 33342034

Citations 11

Authors

Yusuke Tamura

Masato Morikawa

Ryo Tanabe

Kohei Miyazono

Daizo Koinuma

Affiliations

Soon will be listed here.

Abstract

Development of innovative therapeutic modalities would address an unmet clinical need in the treatment of triple negative breast cancer (TNBC). Activation of retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs) such as melanoma differentiation-associated gene 5 (MDA5) and RIG-I in cancer cells is suggested to suppress tumor progression by inducing cell death. Transfection of polyI:C, a conventionally used synthetic double-stranded RNA (dsRNA) analogue that activates RLRs, has been evaluated in clinical trials. However, detailed mechanisms of tumor suppression by RLRs, especially interactions with other signaling pathways, remain elusive. Here, we showed that transfection of polyI:C suppressed transforming growth factor-β (TGF-β) signaling in a MDA5- and RIG-I-dependent manner. We found that suppression of TGF-β signaling by polyI:C promoted cancer cell death, which was attenuated by forced expression of constitutively active Smad3. More detailed analysis suggested that cell death by polyI:C transfection exhibited characteristics of pyroptosis, which is distinct from apoptosis. Therapeutic efficacy of polyI:C transfection was also demonstrated using a mouse model. These results indicated that intratumor administration of polyI:C and related dsRNA analogues may be promising treatments for TNBC through inhibition of the anti-pyroptotic function of TGF-β.

Citing Articles

Types of cell death and their relations to host immunological pathways.

Lu K, Tsai K, Wang Y, Hu W Aging (Albany NY). 2024; 16(15):11755-11768.

PMID: 39120579 PMC: 11346778. DOI: 10.18632/aging.206035.

Pyroptosis and inflammasomes in cancer and inflammation.

Wang J, Hua S, Bao H, Yuan J, Zhao Y, Chen S MedComm (2020). 2023; 4(5):e374.

PMID: 37752941 PMC: 10518439. DOI: 10.1002/mco2.374.

Xihuang pill induces pyroptosis and inhibits progression of breast cancer cells via activating the cAMP/PKA signalling pathway.

Chen C, Yuan S, Chen X, Xie J, Wei Z Am J Cancer Res. 2023; 13(4):1347-1362.

PMID: 37168335 PMC: 10164814.

Identification and validation of the pyroptosis-related long noncoding rna signature to predict the prognosis of patients with bladder cancer.

Wu Z, Zeng J, Wu M, Liang Q, Li B, Hou G Medicine (Baltimore). 2023; 102(8):e33075.

PMID: 36827075 PMC: 11309684. DOI: 10.1097/MD.0000000000033075.

Targeting pyroptosis in breast cancer: biological functions and therapeutic potentials on It.

Chen C, Ye Q, Wang L, Zhou J, Xiang A, Lin X Cell Death Discov. 2023; 9(1):75.

PMID: 36823153 PMC: 9950129. DOI: 10.1038/s41420-023-01370-9.

References

Lafon C, Mathieu C, Guerrin M, Pierre O, Vidal S, Valette A . Transforming growth factor beta 1-induced apoptosis in human ovarian carcinoma cells: protection by the antioxidant N-acetylcysteine and bcl-2. Cell Growth Differ. 1996; 7(8):1095-104. View

Plaza-Sirvent C, Schuster M, Neumann Y, Heise U, Pils M, Schulze-Osthoff K . c-FLIP Expression in Foxp3-Expressing Cells Is Essential for Survival of Regulatory T Cells and Prevention of Autoimmunity. Cell Rep. 2017; 18(1):12-22. DOI: 10.1016/j.celrep.2016.12.022. View

Golden R, Chen B, Li T, Braun J, Manjunath H, Chen X . An Argonaute phosphorylation cycle promotes microRNA-mediated silencing. Nature. 2017; 542(7640):197-202. PMC: 5302127. DOI: 10.1038/nature21025. View

Zhou Z, He H, Wang K, Shi X, Wang Y, Su Y . Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science. 2020; 368(6494). DOI: 10.1126/science.aaz7548. View

Galon J, Bruni D . Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019; 18(3):197-218. DOI: 10.1038/s41573-018-0007-y. View

Loo Y, Gale Jr M . Immune signaling by RIG-I-like receptors. Immunity. 2011; 34(5):680-92. PMC: 3177755. DOI: 10.1016/j.immuni.2011.05.003. View

Vasilaki E, Morikawa M, Koinuma D, Mizutani A, Hirano Y, Ehata S . Ras and TGF-β signaling enhance cancer progression by promoting the ΔNp63 transcriptional program. Sci Signal. 2016; 9(442):ra84. DOI: 10.1126/scisignal.aag3232. View

Lehmann B, Bauer J, Chen X, Sanders M, Chakravarthy A, Shyr Y . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011; 121(7):2750-67. PMC: 3127435. DOI: 10.1172/JCI45014. View

Sheng W, LaFleur M, Nguyen T, Chen S, Chakravarthy A, Conway J . LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade. Cell. 2018; 174(3):549-563.e19. PMC: 6063761. DOI: 10.1016/j.cell.2018.05.052. View

10.

David C, Massague J . Contextual determinants of TGFβ action in development, immunity and cancer. Nat Rev Mol Cell Biol. 2018; 19(7):419-435. PMC: 7457231. DOI: 10.1038/s41580-018-0007-0. View

11.

Cookson B, Brennan M . Pro-inflammatory programmed cell death. Trends Microbiol. 2001; 9(3):113-4. DOI: 10.1016/s0966-842x(00)01936-3. View

12.

Tormo D, Checinska A, Alonso-Curbelo D, Perez-Guijarro E, Canon E, Riveiro-Falkenbach E . Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell. 2009; 16(2):103-14. PMC: 2851205. DOI: 10.1016/j.ccr.2009.07.004. View

13.

Cyprian F, Akhtar S, Gatalica Z, Vranic S . Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer. Bosn J Basic Med Sci. 2019; 19(3):227-233. PMC: 6716092. DOI: 10.17305/bjbms.2019.4204. View

14.

Thompson D, Weigel R . Characterization of a gene that is inversely correlated with estrogen receptor expression (ICERE-1) in breast carcinomas. Eur J Biochem. 1998; 252(1):169-77. DOI: 10.1046/j.1432-1327.1998.2520169.x. View

15.

Maedler K, Fontana A, Ris F, Sergeev P, Toso C, Oberholzer J . FLIP switches Fas-mediated glucose signaling in human pancreatic beta cells from apoptosis to cell replication. Proc Natl Acad Sci U S A. 2002; 99(12):8236-41. PMC: 123051. DOI: 10.1073/pnas.122686299. View

16.

Broz P, Pelegrin P, Shao F . The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol. 2019; 20(3):143-157. DOI: 10.1038/s41577-019-0228-2. View

17.

Brockwell N, Owen K, Zanker D, Spurling A, Rautela J, Duivenvoorden H . Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC. Cancer Immunol Res. 2017; 5(10):871-884. DOI: 10.1158/2326-6066.CIR-17-0150. View

18.

Ehata S, Hanyu A, Hayashi M, Aburatani H, Kato Y, Fujime M . Transforming growth factor-beta promotes survival of mammary carcinoma cells through induction of antiapoptotic transcription factor DEC1. Cancer Res. 2007; 67(20):9694-703. DOI: 10.1158/0008-5472.CAN-07-1522. View

19.

Bhoopathi P, Quinn B, Gui Q, Shen X, Grossman S, Das S . Pancreatic cancer-specific cell death induced in vivo by cytoplasmic-delivered polyinosine-polycytidylic acid. Cancer Res. 2014; 74(21):6224-35. PMC: 4216760. DOI: 10.1158/0008-5472.CAN-14-0819. View

20.

Canadas I, Thummalapalli R, Kim J, Kitajima S, Jenkins R, Christensen C . Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med. 2018; 24(8):1143-1150. PMC: 6082722. DOI: 10.1038/s41591-018-0116-5. View